Crescendo Biologics

Crescendo Biologics
  • Home
  • About Us
    • Overview
    • Investors
    • Strategic Collaborations
  • Our Science
    • Humabody® VH Platform
  • News & Events
    • Press Releases
    • Publications
  • Contact Us
  • LinkedIn
  • Twitter
  • Contact Us
  • Home
  • About Us
    • Overview
    • Investors
    • Strategic Collaborations
  • Our Science
    • Humabody® VH Platform
  • News & Events
    • Press Releases
    • Publications
  • Home
  • About Us
    • Overview
    • Investors
    • Strategic Collaborations
  • Our Science
    • Humabody® VH Platform
  • News & Events
    • Press Releases
    • Publications
  • Contact Us
  • LinkedIn
  • Twitter

Crescendo’s psoriasis, cancer collaborations

Crescendo’s psoriasis, cancer collaborations

S&P Global Market Intelligence

Post navigation

Previous PostPrevious Business Weekly – Crescendo Biologics steps up war against hard-to-treat cancers
Next PostNext Media coverage: Crescendo & BioNTech collaboration

Recent Posts

  • Crescendo Biologics enters pre-clinical collaboration with Orano Med to explore Targeted Alpha Therapy
  • Hello world!
  • Clinical Development
  • Crescendo Biologics and Cancer Research UK sign Clinical Development Partnership to develop CB213, a novel bispecific Humabody® therapeutic
  • Chief Medical Officer

Recent Comments

    Archives

    • July 2020
    • May 2020
    • February 2020
    • January 2020
    • October 2019
    • September 2019
    • July 2019

    Categories

    • Front Page
    • In the News
    • PR & News
    • Uncategorised
    • Videos

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Humabody® and Multibody® are registered trademarks of Crescendo Biologics Limited.
    Privacy and Cookies Notice Cambridge Web Design

    We use cookies to give you a better experience on our website. To find out more, and to manage your preferences, please consult our Privacy and Cookie Notice.